Blog
RSS FeedPosted by Michael Wonder on 29 May 2023
Consultation for various vaccine supply agreements
29 May 2023 - PHARMAC is consulting on potential new supply agreements for multiple vaccines listed in the National Immunisation Schedule. ...
Posted by Michael Wonder on 18 May 2023
Helping with health costs: prescription charge scrapped, providing cheaper medicine
18 May 2023 - The Chris Hipkins Government is reducing the cost of health care for New Zealand households by ...
Posted by Michael Wonder on 14 May 2023
'Would they run out of Viagra?' PHARMAC slammed for huge shortage of HRT
15 May 2023 - Northland women going through menopause are starting to suffer from a raft of “horrible” symptoms caused ...
Posted by Michael Wonder on 11 May 2023
Ovarian cancer: Bay of Plenty mother spends more than $130,000 on treatments
12 May 2023 - Four cancer treatments in three years: $132,775. ...
Posted by Michael Wonder on 10 May 2023
Cases of invasive pneumococcal disease 'sharply' rose after PHARMAC downgraded vaccine programme - study
10 May 2023 - A few years after New Zealand downgraded its vaccine programme against pneumococcal disease, cases of the ...
Posted by Michael Wonder on 01 May 2023
PHARMAC amends funding rules on dispensing of ADHD medicines
1 May 2023 - PHARMAC has announced an amendment to the Pharmaceutical Schedule from 1 June 2023, to align funding rules ...
Posted by Michael Wonder on 01 May 2023
New Zealand Pharmaceutical Schedule - 1 May 2023
The May 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 26 Apr 2023
Time taken for PHARMAC funding decisions ‘too long’, says Medicines NZ
26 April 2023 - It takes the nation's drug-buying agency, PHARMAC, an average of 7.7 years to make funding decisions ...
Posted by Michael Wonder on 20 Apr 2023
PHARMAC announces new Deputy Medical Director Māori
19 April 2023 - PHARMAC has welcomed Dr Kiri Prentice (Ngāi Tūhoe and Ngāti Awa) to the newly established role ...
Posted by Michael Wonder on 11 Apr 2023
PHARMAC funds second treatment for spinal muscular atrophy
11 April 2023 - PHARMAC has announced the funding of risdiplam (Evrysdi) for people with the rare genetic disorder spinal muscular ...
Posted by Michael Wonder on 05 Apr 2023
PHARMAC shares next steps in reviewing rule 8.1b
5 April 2023 - PHARMAC’s consultation on rule 8.1b of the Pharmaceutical Schedule has now closed. ...
Posted by Michael Wonder on 04 Apr 2023
PHARMAC seeking feedback on the COVID-19 anti-viral molnupiravir
4 April 2023 - PHARMAC are consulting on the role of molnupiravir in New Zealand’s portfolio of COVID-19 treatments. ...
Posted by Michael Wonder on 01 Apr 2023
New Zealand Pharmaceutical Schedule - 1 April 2023
1 April 2023 The April 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Mar 2023
Clarity around PHARMAC’s priority lists
30 March 2023 - PHARMAC released its first Clarity Report, containing the latest information about medicines, vaccines, and related products ...
Posted by Michael Wonder on 23 Mar 2023
PHARMAC considers funding rituximab for IgG4 related disease
23 March 2023 - PHARMAC has initiated a consultation today on widening funded access to rituximab (branded as Riximyo) for ...